title: Campylobacter pylori-associated gastritis: attempts to eradicate the bacteria by various antibiotics and anti-ulcer regimens.
abstract: The efficacy of various antimicrobial and anti-ulcer agents on the eradication of Campylobacter pylori in patients with antral gastritis or duodenal ulcers was investigated by several open studies or double-blind, placebo-controlled protocols. Among the anti-ulcer agents, ranitidine, cimetidine or sucraflate had no effect on C. pylori. Colloidal bismuth subcitrate achieved clearance of C. pylori in 40% of treated patients at the end of therapy but a high relapse rate (14/16 patients) was observed after a 6-month follow-up period. The antibacterial agents doxycycline, minocycline, ofloxacin, clindamycin, paromomycin and nifuroxazide failed to eradicate C. pylori in most patients. By contrast, short term elimination of C. pylori could be achieved in more than 90% of patients treated with amoxycillin. However, relapse occurred as a rule in all amoxycillin-treated patients within one month after therapy. Overall, we observed no correlation between the in-vitro activity of the different antibacterial agents and their in vivo efficacy. Development of resistance during therapy does not seem to account for this discrepancy since it occurred only with ofloxacin. On the basis of these results, we conclude that long term eradication of C. pylori from the gastric antrum cannot be achieved after monotherapy either with antibiotics or with bismuth salts.
authors.forename: Y
authors.initials: Y
authors.lastname: Glupczynski
authors.forename: A
authors.initials: A
authors.lastname: Burette
authors.forename: J F
authors.initials: JF
authors.lastname: Nyst
authors.forename: C
authors.initials: C
authors.lastname: De Prez
authors.forename: E
authors.initials: E
authors.lastname: De Koster
authors.forename: M
authors.initials: M
authors.lastname: Deltenre
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002167:Campylobacter / Q000187:drug effects* / Q000472:pathogenicity; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D005773:Gastroscopy; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D001729:Bismuth